Esophagus News

Having GERD, diabetes or osteoporosis in addition to COPD heightened the likelihood for exacerbations, ED visits and hospitalizations, according to results published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.

To honor GERD Awareness Week on Nov. 24 to 30, the International Foundation for Gastrointestinal Disorders launched a campaign theme, “Relief Starts with Awareness,” to boost understanding of symptoms and treatments for the disease.

PHILADELPHIA — On-demand vonoprazan effectively reduced heartburn symptom severity in patients with nonerosive reflux disease within 1 hour of treatment, according to data presented at the ACG Annual Scientific Meeting.

PHILADELPHIA — A once-weekly 360 mg dose of cendakimab sustained improvements in symptoms and endoscopic/histologic features of eosinophilic esophagitis at 48 weeks, according to data presented at the ACG Annual Scientific Meeting.

BOSTON — The odds for mortality, ventilation and septic shock among adults hospitalized with COPD went down if they also had GERD, according to data presented at the CHEST Annual Meeting.

Among patients with Barrett’s esophagus, every 5 kg/m2 increase in BMI was associated with up to a 6% relative increase in the risk for malignant progression, according to a systematic review and meta-analysis.

The biomarker-based Esopredict determined that patients with Barrett’s esophagus who were stratified as higher risk were 6.4-times more likely to progress to high-grade dysplasia or esophageal adenocarcinoma within 5 years, research showed.

“Aggressive” combination therapy for gastroesophageal reflux disease improved survival among patients with systemic sclerosis and interstitial lung disease, according to data published in Arthritis Research & Therapy.

Researchers found associations between Index of Severity for Eosinophilic Esophagitis scores and select clinical features across categories of disease severity, according to a study published in The Journal of Allergy and Clinical Immunology.